Intellia Therapeutics Stock Could Roar in the Next Bull Market. Here's Why.
Even after rising 30% so far this year, shares of Intellia Therapeutics (NASDAQ: NTLA) could easily experience another leg up if there's a bull market in the latter half of 2023. With positive readouts from its clinical trials, two powerful collaborators in its corner, and a strong balance sheet, Intellia has a lot of elements traditionally associated with biotechs having a high chance of success.
And that means it could be smart to buy a few shares, especially if you're willing to hold for a few years until it has a chance to get one of its medicines out the door. So here's what you need to know about how and why it's well- positioned to grow.
On June 11, Intellia reported interim data from its phase 1/2 gene-editing therapy trial investigating its therapy for hereditary angioedema (HAE), and the results appear to be stellar so far.
Source Fool.com
Intellia Therapeutics Inc Stock
With 17 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 60 € there is potential for a 146.91% increase which would mean more than doubling the current price of 24.3 € for Intellia Therapeutics Inc.
